Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.41 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20447683 | 1.00 | LOXL2 (0.47) | LOXL2MBOAT4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4851284 | 0.98 | LOXL2 (0.48) | LOXL2MBOAT4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL17680520 | 0.83 | CYP11B2 (0.47) | LOXL2NSD2GRM5 | |
| SCHEMBL453493 | 0.78 | KDM4E (0.42) | LOXL2MBOAT4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL2633134 | 0.78 | CYP2A6 (0.48) | LOXL2MBOAT4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL23171396 | 0.78 | MEN1 (0.43) | LOXL2MBOAT4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL6245066 | 0.78 | KDM4E (0.42) | LOXL2MBOAT4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL450943 | 0.78 | KDM4E (0.42) | MBOAT4KDM4EALDH1A1L3MBTL1LMNA | |
| SCHEMBL17266360 | 0.78 | KDM4E (0.42) | LOXL2MBOAT4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL17845779 | 0.78 | KDM4E (0.42) | LOXL2MBOAT4KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187712-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3814343-B1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20210276991-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2021-09-09 | — | — | US | disclosed |
| EP-3814343-A1 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200277262-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES | JONES BENJAMIN (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3676251-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES USEFUL AS HIF PROLYL HYDROXYLASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019060850-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES USEFUL AS HIF PROLYL HYDROXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-03-28 | — | — | WO | disclosed |
| EP-1968977-B1 | Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| EP-1968977-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZOÝ1, 5-A¨PYRIDINE DERIVATIVES | F. Hoffmann-la Roche AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| US-7399769-B2 | Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-6774110-B2 | ANTITHROMBOTIC ACTIVITY AND HIGH ORAL BIOAVAILABILITY; E.G. N-AMINOSULFONYL-D-DIPHENYLALANYL-L-PROLYL-((4-AMIDINOPHENYL)METHYL)AMIDE | LG LIFE SCIENCES LTD. (KR) | 2004-08-10 | — | — | US | disclosed |
| US-20040102448-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-20040006230-A1 | Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases | PHARMACIA CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6664255-B1 | 1-alkylamido-3-amino substituted; inhibiting serine proteases | PHARMACIA CORPORATION | 2003-12-16 | — | — | US | disclosed |
| EP-1292579-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | LG LIFE SCIENCES LTD. (KR) | 2002-11-14 | — | — | US | disclosed |
| CN-1351595-A | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CO (US) | 2002-05-29 | — | — | CN | disclosed |
| EP-1202975-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001087854-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2000069834-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102448-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, TFPI2 | GAA 1404/4885CYP19A1 1127/4885LOXL2 1706/4885 |
| US-12187712-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | GAA 2646/4885CYP19A1 4503/4885LOXL2 1591/4885 |
| US-20200277262-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES | P4HA1, HRH3, HRH1 | GAA 1488/4885CYP19A1 329/4885LOXL2 1915/4885 |
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | F2, SERPINC1, TFPI | GAA 3638/4885CYP19A1 3343/4885LOXL2 2947/4885 |
| US-20040006230-A1 | Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases | PRSS1, SERPINC1, SERPINE1 | GAA 777/4885CYP19A1 1650/4885LOXL2 1035/4885 |
| US-20210276991-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | GAA 2646/4885CYP19A1 4503/4885LOXL2 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.